^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    oxaliplatin

    i
    Other names: 1 OHP, 1670 RB, L OHP, NSC 266046, PR 54780, RP 54780, SR 96669, 1670 RB7
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, DNA cross linking agent
    Related drugs:
    1d
    Percutaneous electrical nerve stimulation as a non-pharmacological strategy in oxaliplatin-induced neuropathy: evidence from a randomized clinical trial (ACTRN12624001390572)
    P=N/A, N=20, Completed, Universidad Europea de Madrid | Recruiting --> Completed
    Trial completion
    |
    oxaliplatin
    1d
    ALDH3A2 targets arachidonic acid to promote cell metastasis in TNBC via AMPK/m-TOR signaling pathway. (PubMed, Breast Cancer Res)
    Our work establishes ALDH3A2 as a pivotal regulator of lipid metabolic reprogramming in TNBC metastasis, providing mechanistic insights into AA-mediated tumor progression. These findings position ALDH3A2 as a promising therapeutic target and prognostic biomarker for TNBC management.
    Journal
    |
    AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
    |
    oxaliplatin
    1d
    Formononetin protects against oxaliplatin-induced peripheral neurotoxicity via Nrf2/HO-1 antioxidant pathway without impairing anticancer efficacy. (PubMed, Neurotoxicology)
    Importantly, unlike the ROS scavenger N-acetylcysteine (NAC), which decreased the anticancer effectiveness of both oxaliplatin and paclitaxel, formononetin maintained their anticancer effects in colorectal cancer HT29 cells and cervical cancer SiHa cells. Taken together, formononetin holds potential as a neuroprotectant to prevent oxaliplatin-induced neurotoxicity without compromising anticancer efficacy.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • HMOX1 (Heme Oxygenase 1)
    |
    paclitaxel • oxaliplatin
    1d
    Biliary Drainage Plus HAIC in Locally Advanced pCCA (clinicaltrials.gov)
    P2, N=127, Completed, Peking University | Recruiting --> Completed | Trial completion date: May 2026 --> Oct 2025 | Trial primary completion date: Mar 2025 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • oxaliplatin
    1d
    Induction FLOT With CROSS CRT for Esophageal Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • docetaxel • oxaliplatin
    2d
    A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Sun Yat-sen University | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    2d
    TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    2d
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread (clinicaltrials.gov)
    P1/2, N=768, Recruiting, Boehringer Ingelheim | N=582 --> 768 | Trial completion date: Sep 2029 --> Jan 2029 | Trial primary completion date: Sep 2029 --> Jan 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii) • Hernexeos (zongertinib)
    2d
    CEIL: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=198, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Enweida (envafolimab)
    2d
    Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma (clinicaltrials.gov)
    P3, N=820, Not yet recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Oct 2025 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    2d
    Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer. (clinicaltrials.gov)
    P3, N=70, Not yet recruiting, Ain Shams University
    New P3 trial
    |
    oxaliplatin • vincristine
    3d
    GLOX-PEN: Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy (clinicaltrials.gov)
    P=N/A, N=84, Recruiting, AC Camargo Cancer Center
    New trial
    |
    oxaliplatin